Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02966782
Title A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.

myelodysplastic syndrome


Azacitidine + Venetoclax


Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.